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MULTIPLEXED GENOTYPING OF HUMAN MINOR HISTOCOMPATIBIL-
ITY ANTIGENS
Pietz, B.C.; DuChateau, B.K.; Warden, M.B.; Ellis, T.M. The Blood
Center of S.E. Wisconsin, Milwaukee, WI.
Minor histocompatibility antigens (mHA) induce T cell medi-
ated immune responses that have been associated with increased
risk of graft versus host disease and allograft rejection. Unlike HLA
genes, mHA are encoded by genetically and functionally unrelated
genes located throughout the chromosome. The role of mHA in
stem cell transplantation and the frequencies of mHA alleles in
large study populations remain unknown due in part to the lack of
a suitable high throughput method for mHA genotyping. Here we
describe the development and utility of a single tube, expandable,
multiplexed assay for genotyping mHA (HA-1, HA-2, HA-3,
HA-8, HB-1, CD31125, and CD31563) using the Luminex plat-
form. The assay utilizes a multiplexed allele-independent gated
ampliﬁcation of mHA genes followed by differential detection of
allele-speciﬁc primer products using the MultiCode system (Era-
gen Biosciences, Madison, WI). The alleles are interrogated using
a multiplex allele-speciﬁc primer extension reaction with primers
tagged with EraCodes, the products hybridized to Luminex beads,
and the hybridization duplex detected using streptavidin-PE. Us-
ing this assay, we generated an estimate of mHA allele frequencies
in a limited local donor population and are assessing the inﬂuence
of mHA disparities on outcomes of stem cell transplantation in a
large cohort of unrelated recipient-donor pairs.
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MOLECULAR CHARACTERIZATION OF HLA-A MISMATCHES FOR MOD-
ELING OUTCOMES ANALYSES
Baxter-Lowe, L.A.1; Maiers, M.2; Spellman, S.2; Fernandez-Vina,
M.3; Horowitz, M.4; Haagenson, M.2; Hurley, C.5 1. UCSF, San
Francisco, CA; 2. NMDP, Minneapolis, MN; 3. M.D. Anderson, Hous-
ton, TX; 4. Medical College of Wisconsin, Milwaukee, WI; 5. George-
town University, Washington, DC.
For allogeneic transplant candidates who have no HLA matched
donor, there are no well accepted guidelines for selecting an HLA
mismatched (MM) donor. To provide a foundation for developing
new models for ranking HLA MM donors, this investigation fo-
cuses on HLA-A MM because single HLA-A MM are observed in
a large proportion of patients. The molecular characteristics of 832
HLA-A MM were examined in 3,687 unrelated donor-recipient
pairs from NMDP facilitated transplants which had retrospective
high resolution HLA typing. There are a few high frequency MM
combinations that constitute a large proportion of the MM: 0201
vs 0205 (8%), 0201 vs 0206 (8%), 6801 vs 6802 (4%), 3001 vs 3002
(4%), and 0201 vs 6801 (4%). There are 12 MM combinations that
occur10 times and comprise 25% of the MM combinations. The
remaining MM combinations, which constitute 46% of the total,
are relatively infrequent and include 95 combinations that occur
only once in this population. Comparison of the protein sequences
of the peptide binding domain of mismatched HLAs revealed 1–28
amino acid differences. Of these, 17% were single amino acid
differences and 16% had 2–3 amino acid differences. Approxi-
mately 70% of MM amino acids were located in positions that alter
the environment of the bound peptide. For these residues, small
differences in the properties of the amino acid side chains can have
substantial effects on T cell allorecognition. Many HLA-A dispar-
ities (63%) were accompanied by additional HLA-A, -B, -C,
and/or -DRB1 MM. This emphasizes the need for models that
detect additive, synergistic, dominant and permissive effects. The
characteristics of HLA-A disparities suggest that traditional HLA
MM criteria that have been used for outcomes analyses may ob-
scure important molecular characteristics that underlie detrimental
or permissive HLA MM. The characteristics of the HLA-A MM
are likely to be unique and HLA locus-speciﬁc characteristics
should be carefully considered in future study designs. A multifac-
eted approach is proposed for studying the relationship between
HLA disparity and transplant outcomes that determines the risks
associated with (1) high/intermediate frequency disparities, (2)
categories of functionally similar HLA disparities, and (3) multiple
HLA MM with complex interactions. This multifaceted approach
is likely to provide clinically useful guidelines for selection of MM
donors and explain some of the controversies in the scientiﬁc
literature.
IMMUNE RECONSTITUTION
157
IMPACT OF PLASMACYTOID DENDRITIC CELL RECOVERY ON OUT-
COME AFTER REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM
CELL TRANSPLANTATION
Mohty, M.; Blaise, D.; Faucher, C.; Bardou, V.J.; Gastaut, J.A.; Viens,
P.; Olive, D.; Gaugler, B. Institut Paoli-Calmettes, Marseille, France.
Among DC subsets, the reconstitution of the natural type I-in-
terferon-producing plasmacytoid DCs (PDC) has been proposed
to play a major role in establishing immune competence, given the
capacity of PDCs to efﬁciently expand either speciﬁc cytotoxic T
lymphocytes, or to promote regulatory T cells, contributing to an
impaired immune response. Therefore, we investigated the impact
of circulating PDCs measured at 3 months after RIC-allo-SCT, in
54 pts who received a RIC-allo-SCT from an HLA-identical sib-
ling, in order to determine whether this could provide a convenient
indicator for long term outcome. The median absolute count of
PDCs measured at 3 months was 0.725/L (range, 0–23.2). In a
multiple logistic regression analysis including relevant parameters,
only the absence of clinically signiﬁcant grade II-IV acute GVHD
was associated with an improved PDC recovery (P0.003;
OR6.4; 95% CI, 1.9–22). We also investigated whether PDCs
recovered after allo-SCT are functional in response to viral stim-
ulation. Pts experiencing grade 0-I aGVHD could secrete signiﬁ-
cantly higher amounts of IFN-alpha as compared to pts with grade
II-IV aGVHD (mean, 91 pg/ml vs. 0 pg/ml respectively; P0.002),
likely highlighting the deleterious impact of corticosteroids ther-
apy on PDC function. The CD34 stem cell dose and other
lymphoid subsets infused with the allograft did not affect PDC
recovery. Though PDC count could not predict death from pro-
gression or relapse, pts with a high PDC recovery proﬁle had an
improved overall survival (OS; P0.03), in contrast to pts with a
low PDC recovery proﬁle who had an increased incidence of late
transplant-related mortality (GVHD, infections) (P0.03). In ad-
dition, the overall incidence of late infections (viral, fungal and
bacterial) was signiﬁcantly higher in the low PDC recovery group
as compared to the high PDC recovery group (59% vs. 19%;
P0.002), illustrating the importance of PDCs in anti-infectious
immune responses. In a multivariate analysis, only a high PDC
count was signiﬁcantly predictive of a decreased risk of death
(P0.04; RR0.34; 95% CI, 0.12–0.96). The role and impact of
rare immune effector cells would tend to be more evident in truly
RIC and less toxic regimens. In this study, we could show that
monitoring of PDCs may be useful for pts management (closer
surveillance, infection prophylaxis), and may have a signiﬁcant
impact on the probability of a favorable outcome in the context of
RIC-allo-SCT.
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INTERLEUKIN-7 IMPROVES RECONSTITUTION OF ANTIVIRAL CD4 T
CELLS
Lu, H.; Zhao, Z.; Kalina, T.; Kiem, H.-P.; Storek, J. Fred Hutchinson
Cancer Research Center, Seattle, WA.
We evaluated whether long-term (2 months) administration of
interleukin-7 (IL7) hastens immune recovery in baboons rendered
severely lymphopenic by total body irradiation and anti-thymocyte
globulin. Four baboons were treated with recombinant baboon IL7
and three baboons with placebo. Median CD4 T cell count at the
end of IL7/placebo treatment was higher in the IL7-treated ani-
mals (2,262 vs 618/ml, p0.03). This appeared to be a result of
peripheral expansion rather than de novo generation. Median cy-
tomegalovirus-speciﬁc IFNg-producing CD4 T cell count at the
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